Harrow, Inc.
NASDAQHROW entered its Q1 print as one of the most shorted small-cap pharma names on Nasdaq. The stock's 24% collapse confirms that heavy positioning wasn't misplaced. Harrow reported Q1 results after the close on May 11. EPS missed by $0.39 — a 39-cent gap that spooked a market already braced for disappointment. The stock fell 24% over two sessions to close at $29.03, wiping out the…
Snapshot as of 13 May 2026
HROW entered its Q1 print as one of the most shorted small-cap pharma names on Nasdaq. The stock's 24% collapse confirms that heavy positioning wasn't misplaced. Harrow reported Q1 results after the close on May 11.…
Harrow, Inc. heads into its Q1 2026 earnings today with a short book that remains stubbornly elevated — and a stock that has pulled back sharply from this year's highs. Short sellers are not backing down. At 17% of the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for HROW — free to start on ORTEX.
Sign up for free →Open HROW on ORTEX